GlassScriptPhysician profile
Husang David Lee
NPI 1487237053
$4,721.80
in general payments reported to CMS, 2019-2025
13 companies · $2,613 in 2025
The $2,613 reported for 2025 was more than what 88% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,360 · 2023: $239 · 2024: $510 · 2025: $2,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393 · Travel and Lodging: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.52 |
| Travel and Lodging | $969.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,484.78 | 2024-2025 | Ortholoc 3di, Actishield, Prostep |
| Kairos Surgical INC | $1,238.73 | 2022-2024 | |
| Smith+Nephew, INC. | $622.84 | 2022-2025 | Stravix, Stravix Pl, Grafix Pl |
| Medtronic, INC. | $285.99 | 2024-2025 | Venaseal, Intellis Adaptivestim, Inceptiv |
| Paragon 28, INC. | $211.79 | 2025 | Gorilla |
| Fortis Surgical, LLC | $195.41 | 2024-2025 | |
| Tactile Systems Technology INC | $149.95 | 2025 | Flexitouch Plus, Nimbl |
| Orthofix Medical, INC. | $133.43 | 2024 | Physio-Stim |
| Convatec INC. | $124.44 | 2023-2025 | |
| Averitas Pharma INC. | $118.80 | 2025 | Qutenza |
| Kerecis Limited | $74.69 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $62.28 | 2024 | Cygnus Dual |
| Bioventus LLC | $18.67 | 2025 | Exogen Ultrasound Bone Healing System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husang Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.